CreoSG Secures Canadian Patent for MERS Vaccine
On June 26, CreoSG announced that it has obtained a Canadian patent for its recombinant VSV vector-based MERS vaccine, which was registered through its subsidiary, Smagen Canada.
The recombinant VSV platform technology (brand name: SUV-MAP) is a core technology for developing various vaccines. It enables the creation of recombinant viruses carrying target antigen genes, which can then be mass-produced in cultured cells and used as vaccine raw materials. CreoSG is currently developing AIDS vaccines, COVID-19 vaccines, and hantavirus vaccines using SUV-MAP, through its own vaccine research institute and Smagen Canada.
The VSV-MERS vaccine is a product that maximizes vaccine efficacy by loading the MERS-CoV viral envelope protein onto the SUV-MAP vaccine platform, which is based on a recombinant VSV vector created through genetic recombination methods. This vaccine was also patented in Saudi Arabia in March 2026.
Middle East Respiratory Syndrome (MERS) is a viral respiratory disease caused by the Middle East Respiratory Syndrome coronavirus (MERS-CoV), first identified in Saudi Arabia in 2012. The disease primarily attacks the respiratory system and can cause a range of symptoms from mild to severe. In particular, it can become fatal if it progresses to pneumonia. As there are currently no approved vaccines or specific antiviral treatments, the need for a vaccine is even more pronounced.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from CreoSG stated, "With the acquisition of a Canadian patent following Saudi Arabia, our technological capabilities have once again been recognized," adding, "We are now planning a vaccine development roadmap that will enable us to commercialize the MERS vaccine."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.